You are here
Clinical study of AdV-tk radiogene therapy for glioma
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44CA107745-01
Agency Tracking Number: CA107745
Amount:
$758,386.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Timeline
Solicitation Year:
2004
Award Year:
2004
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
ADVANTAGENE, INC.
160 PAULSON RD
WABAN, MA
02468
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: ESTUARDO Aguilarcordova
Phone: (617) 916-5445
Email: EAGUILAR@ADVANTAGENE.COM
Phone: (617) 916-5445
Email: EAGUILAR@ADVANTAGENE.COM
Business Contact
Name: AMANDA DAVIS
Phone: (617) 916-5445
Email: ADAVIS@ADVANTAGENE.COM
Phone: (617) 916-5445
Email: ADAVIS@ADVANTAGENE.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovir
* Information listed above is at the time of submission. *